Q-omics provides the consensus-scored MIR25 profile across patient tissues and cancer cell-line models. MIR25 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR25 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MIR25 RNA expression shows 17,004 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where MIR25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR25 survival associations across molecular data types. MIR25 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR25 RNA expression–survival associations across cancer types. High MIR25 expression shows unfavorable associations in ACC, KIRC and COAD, but favorable associations in HNSC, PAAD and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR25 RNA expression.
This table summarizes MIR25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR25 shows higher tumor expression in COAD, KIRC, HNSC, BLCA, READ and ESCA. The COAD box plot shows higher MIR25 RNA expression in tumor versus normal tissue (log2 FC = +2.122, t-test p < 0.001).
This table shows molecular features associated with MIR25 in patient tissues and cancer cell lines. In patient samples, MIR25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
